Refine by
Develop New Diagnostic Articles & Analysis: Older
25 articles found
Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. ...
Alfa Cytology has launched ovarian cancer therapy development services. Alfa Cytology, a prominent services provider in oncology, has launched its cutting-edge ovarian cancer therapy development services. ...
Additionally, multiplex cytokine analysis is a valuable tool in vaccine development and drug discovery, providing real-time feedback on immune modulation. ...
In the rapidly evolving world of biotechnology, synthetic peptides have emerged as a pivotal component with wide-ranging applications in medical research, diagnostics, and therapeutic developments. These lab-created sequences of amino acids mimic naturally occurring peptides and are instrumental in advancing scientific discoveries and pharmaceutical innovations. ...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research. ...
Cytoskeleton Technologies ·High-Resolution Microscopy The development of advanced microscopy techniques, such as super-resolution microscopy (e.g., STORM, PALM), has drastically improved our ability to visualize the cytoskeleton. ...
They have the advantages of small size, high stability, and good penetration, and therefore have a wide range of application prospects in the fields of clinical treatment, diagnostic reagent development, etc.Characteristics of NanobodiesThe size of nanobodies usually ranges between 10-15kDa, which is only 1/10 of the size of regular antibodies. ...
Identification of biomarkers Luminex technology is also being used to identify new biomarkers for cancer. By profiling cytokine levels in cancer patients, researchers are able to identify patterns and correlations between cytokine levels and different stages of cancer development and progression. This information can then be used to develop ...
Identification of biomarkers Luminex technology is also being used to identify new biomarkers for cancer. By profiling cytokine levels in cancer patients, researchers are able to identify patterns and correlations between cytokine levels and different stages of cancer development and progression. This information can then be used to develop ...
Identification of key lipids and related enzymes can help to identify potential abnormalities in metabolic pathways or pathogenic mechanisms, and eventually develop effective diagnostic and therapeutic tools. Depending on the focus of the study, lipidomics can be applied to the following pharmaceutical research. ...
However, thanks to advancements in medical research and technology, significant progress has been made in the field of rare disease research, from developing accurate diagnostic tools to making effective small-molecule drugs. ...
Karyotype analysis refers to the pairing and grouping of chromosomes to reveal whether the organism accords with the inherent chromosomal characteristics, to determine if the organism has chromosomal abnormalities. Karyotype analysis can detect whether there are abnormalities in chromatin length, centromere position, the ratio of long and short arms, and the presence or absence of satellites. ...
These diseases often come with significant challenges, including accurate diagnosis, availability of effective treatments, and limited resources for research and development. However, recent advancements in diagnostics technology hold promise for speeding up the field of rare disease therapies. ...
Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and phenotype by adopting a personalized treatment methodology for ...
Clarice Reid, a true leader and advocate for those affected by sickle cell disease and BioMark Diagnostics Inc. a diagnostic company focused in developing better cancer care management solutions. ...
X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood. The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially ...
Carrie Fisher was an American actress most well known for her role as Princess Leia in the Star Wars films (1977-1983 and 2015-2019). She was the daughter of singer Eddie Fisher and actress Debbie Reynolds. Carrie Fisher wrote the semi-autobiographical book Postcards from the Edge and the autobiography Wishful Drinking, which she turned into a one-woman stage show. She was open throughout her ...
Carrie Fisher: Bipolar disorder Carrie Fisher was an American actress most well known for her role as Princess Leia in the Star Wars films (1977-1983 and 2015-2019). She was the daughter of singer Eddie Fisher and actress Debbie Reynolds. Carrie Fisher wrote the semi-autobiographical book Postcards from the Edge and the autobiography Wishful Drinking, which she turned into a one-woman stage ...
A cash raising is inevitable. There is positive news about the company’s oral health product and the optimal bacteria/lysate mix is being assessed prior to human studies. There could be good news to come from Croda, which is SkinBioTherapeutics’ partner in the cosmetics sector. ...
SubB2M-based immunohistochemistry applications represent a new product opportunity for SubB2M in the $1.9b immunohistochemistry market. ...